Neurology Advisor spoke with Klaus Schmierer, MBBS, PhD, to discuss new evidence suggesting a protective antibody response following vaccination in patients with MS taking MAVENCLAD.
Study researchers assessed the morphometric and microstructural gray matter differences between primary progressive and relapsing remitting multiple sclerosis.
Study researchers conducted a narrative review to update the public on the new classification of trigeminal neuralgia, clinical signs, pathophysiology, and management.
A team of investigators sought to determine whether κ- and λ-FLC index may predict early multiple sclerosis disease activity independent of demographics, clinical, and MRI characteristics.
Researchers called for effective tools for earlier identification of secondary progressive MS to improve long-term outcomes in patients with the disease.
This case study examines 2 patients with relapsing remitting multiple sclerosis, under dimethyl fumarate treatment, who developed severe herpes zoster infection.
